JP4532109B2 - 新規オリパビン誘導体および医薬としてのその使用 - Google Patents

新規オリパビン誘導体および医薬としてのその使用 Download PDF

Info

Publication number
JP4532109B2
JP4532109B2 JP2003528819A JP2003528819A JP4532109B2 JP 4532109 B2 JP4532109 B2 JP 4532109B2 JP 2003528819 A JP2003528819 A JP 2003528819A JP 2003528819 A JP2003528819 A JP 2003528819A JP 4532109 B2 JP4532109 B2 JP 4532109B2
Authority
JP
Japan
Prior art keywords
compound
formula
methyl
pharmaceutically acceptable
buprenorphine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003528819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506985A5 (enExample
JP2005506985A (ja
Inventor
ジョオン、ボフォ
ゴン、ゼフィ
ワン、ヤピン
リウ、ヨンシャオ
Original Assignee
インスティチュート オブ ファーマコロジー アンド トクシコロジー アカデミー オブ ミリタリー メディカル サイエンス、 ピー．エル．エー．チャイナ
ゼジアン シアンジュ ファーマシューテイカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスティチュート オブ ファーマコロジー アンド トクシコロジー アカデミー オブ ミリタリー メディカル サイエンス、 ピー．エル．エー．チャイナ, ゼジアン シアンジュ ファーマシューテイカル カンパニー リミテッド filed Critical インスティチュート オブ ファーマコロジー アンド トクシコロジー アカデミー オブ ミリタリー メディカル サイエンス、 ピー．エル．エー．チャイナ
Publication of JP2005506985A publication Critical patent/JP2005506985A/ja
Publication of JP2005506985A5 publication Critical patent/JP2005506985A5/ja
Application granted granted Critical
Publication of JP4532109B2 publication Critical patent/JP4532109B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2003528819A 2001-09-14 2002-09-13 新規オリパビン誘導体および医薬としてのその使用 Expired - Lifetime JP4532109B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB011421495A CN1233645C (zh) 2001-09-14 2001-09-14 新的东罂粟碱衍生物及其医药用途
PCT/CN2002/000642 WO2003024972A1 (en) 2001-09-14 2002-09-13 New oripavine derivatives and their uses as medicines

Publications (3)

Publication Number Publication Date
JP2005506985A JP2005506985A (ja) 2005-03-10
JP2005506985A5 JP2005506985A5 (enExample) 2009-10-01
JP4532109B2 true JP4532109B2 (ja) 2010-08-25

Family

ID=4676657

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003528819A Expired - Lifetime JP4532109B2 (ja) 2001-09-14 2002-09-13 新規オリパビン誘導体および医薬としてのその使用

Country Status (8)

Country Link
EP (1) EP1439179B1 (enExample)
JP (1) JP4532109B2 (enExample)
CN (1) CN1233645C (enExample)
AT (1) ATE390428T1 (enExample)
DE (1) DE60225827D1 (enExample)
MX (1) MXPA04002422A (enExample)
WO (1) WO2003024972A1 (enExample)
ZA (1) ZA200402733B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1939920B (zh) * 2005-09-29 2011-08-31 中国人民解放军军事医学科学院毒物药物研究所 东罂粟碱类化合物及其医药用途
ES2329296T3 (es) * 2006-01-05 2009-11-24 Mallinckrodt, Inc. El uso de oripavina como material de partida para buprenorfina.
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
US8546572B2 (en) * 2008-03-31 2013-10-01 Sun Pharmaceutical Industries Limited Process for the preparation of morphinane analogues
AU2009300390B2 (en) * 2008-09-30 2015-05-14 SpecGx LLC Processes for the production of buprenorphine with reduced impurity formation
ES2462756T3 (es) 2008-09-30 2014-05-26 Mallinckrodt Llc Procedimientos de síntesis de alcaloides opiáceos con formación reducida de impurezas
NZ592005A (en) 2008-09-30 2013-03-28 Mallinckrodt Llc Process for the preparation of a N-alkylated ketomorphinan by selective catalytiC hydrogen transfer reduction
ES2477190T3 (es) 2008-09-30 2014-07-16 Mallinckrodt Llc Procedimiento de reciclaje para aumentar el rendimiento de una reacción de Grignard en la preparación de derivados alcaloides opiáceos
CA2738089C (en) 2008-09-30 2017-07-18 Mallinckrodt Inc. Processes for the hydrogenation of opiate alkaloid derivatives
EP2342207B1 (en) 2008-09-30 2015-11-11 Mallinckrodt LLC Processes for the alkylation of norbuprenorphine with reduced impurity formation
TWI630208B (zh) * 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
CN102462680B (zh) * 2010-11-04 2016-08-03 中国人民解放军军事医学科学院毒物药物研究所 噻吩诺啡的长效缓释微球及其组合物和制备方法
CN102382118A (zh) * 2011-05-23 2012-03-21 浙江仙琚制药股份有限公司 一种7ɑ-乙酰基-6,14-乙基桥四氢蒂巴因的制备方法
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
EP3023427A1 (en) 2014-11-19 2016-05-25 Siegfried AG Improved method of manufacturing buprenorphine and analogues thereof from oripavine
EP3067357A1 (en) 2015-03-11 2016-09-14 Siegfried AG Method of manufacturing stereoisomers of buprenorphine and analogues thereof
GB2550566A (en) 2016-05-19 2017-11-29 Chapelglade Ltd Mattress evaluation system and method
CN108530452B (zh) * 2017-03-01 2023-02-03 泰州华元医药科技有限公司 高效抗成瘾药物
EP4613751A1 (en) 2024-03-07 2025-09-10 Siegfried AG Method of making chemical compounds useful for the synthesis of buprenorphine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB925723A (en) * 1960-09-05 1963-05-08 J F Macfarlan & Company Ltd Novel thebaine derivatives
US3474101A (en) * 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
DE2230154A1 (de) * 1972-06-21 1974-01-17 Boehringer Sohn Ingelheim N-(heteroaryl-methyl)-6,14-endoaetheno7alpha-hydroxyalkyl-tetrahydro-nororipavine und -thebaine, deren hydrierungsprodukte und saeureadditionssalze sowie verfahren zu deren herstellung
KR100204659B1 (ko) * 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물

Also Published As

Publication number Publication date
JP2005506985A (ja) 2005-03-10
WO2003024972A1 (en) 2003-03-27
CN1233645C (zh) 2005-12-28
EP1439179A4 (en) 2005-10-12
ZA200402733B (en) 2005-02-23
ATE390428T1 (de) 2008-04-15
EP1439179B1 (en) 2008-03-26
WO2003024972A8 (en) 2004-06-17
MXPA04002422A (es) 2005-04-11
CN1408714A (zh) 2003-04-09
EP1439179A1 (en) 2004-07-21
DE60225827D1 (de) 2008-05-08

Similar Documents

Publication Publication Date Title
JP4532109B2 (ja) 新規オリパビン誘導体および医薬としてのその使用
US9932349B2 (en) 8-carboxamido-2,6-methano-3-benzazocines
CN103405431B (zh) 阿片和阿片样化合物及其用途
JP3843456B2 (ja) モルヒナン誘導体および医薬用途
US5739145A (en) Antitussive agents
AU2002227135A1 (en) 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
CN105246897B (zh) 阿片样缩酮化合物和其用途
JP2002501923A (ja) 治療用化合物
US7923454B2 (en) Opioid and opioid-like compounds and uses thereof
JPH1087667A (ja) モルフィナンヒドロキサム酸化合物
US7501433B2 (en) Opioid and opioid-like compounds and uses thereof
US20120114599A1 (en) Opioid and opioid-like compounds and uses thereof
US7119100B2 (en) Oripavine derivatives and their uses as pharmaceuticals
GB1590155A (en) Cis-4a-phenyl-2,3,4,4a,5,6,7,7a-octahydro-1h-2-pyrindines and pharmaceutical compositions containing them
JPS5919096B2 (ja) ベンゾモルフィナン誘導体の製造法
US4183939A (en) Glaucine analgesic method
US3767658A (en) N benzoylalkylmorphinan derivatives and salts thereof
TWI430992B (zh) 類鴉片及類似之類鴉片化合物及其用途（二）
JPS6330897B2 (enExample)
JPWO1998043978A1 (ja) モルヒナン誘導体及び医薬用途
JPWO2001014382A1 (ja) モルヒナン４級アンモニウム塩誘導体を有効成分とする鎮痛薬
HK1192711B (en) Opioid and opioid-like compounds and uses thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050811

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090713

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090721

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090925

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20091228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100125

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100511

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100610

R150 Certificate of patent or registration of utility model

Ref document number: 4532109

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130618

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130618

Year of fee payment: 3

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term